Metabolomics Market to Attain USD 11.32 Billion Size by 2034

Metabolomics Market Size, Trends, Companies and Regional Growth Analysis

The global metabolomics market was evaluated at US$ 2.83 billion in 2023 and is expected to reach around US$ 11.32 billion by 2034, growing at a CAGR of 13.43% from 2024 to 2034. The growth of the metabolomics market is driven by the ability to provide details of metabolic states and global biochemical events affecting cells or biological systems.

Unlock Infinite Advantages: Subscribe to Annual Membership

Market Overview

The metabolomics market has grown rapidly as a result of metabolomics, which combines techniques to identify and analyze cellular metabolites using advanced analytical methods with statistical and multivariate methods for data extraction and interpretation. Significant investments have been made in the development of analytical methods for different cellular products such as gene expression (transcripts), proteins, and metabolites. This method has been applied to many different biological systems using GC-MS, including plant, microbial, urine, and plasma. Metabolomics uses additional studies such as LC-MS/MS, GC-MS, and/or NMR to identify and characterize as many metabolites as possible. It can also be used for metabolic fingerprints (or footprints of exogenous and/or secreted metabolites).

Market Trends

• In June 2023, the American Society for Mass Spectrometry (ASMS) - Waters Corporation announced updates to the SELECT SERIES MRT System that improve the specificity and usability of UPLC-MS/MS metabolomics and drug discovery applications, including mass spectrometry experiments. The MRT systems now offer 50% higher resolution, enabling 300,000 FWHM resolution, 3x faster scan speeds, and the ability to acquire millions of true locations, driving growth in the metabolomics market.
• The next generation of high-resolution mass spectrometers (MS) is designed to combine proteomics, metabolomics, biopharmaceutical characterization, and small molecule analysis with the performance required for research and high-throughput analysis. The new system will help support discovery and analysis, improve accuracy, and increase business confidence while simplifying operations and accelerating time to profit, thus paving the way for the development of the market.
• Horizon Europe is the EU's main funding program for research and innovation. Horizon Europe's budget for the period 2021-2027 is €93.5 billion, as determined under the Medium Term (MTR) of the multiannual financial model.
• TMIC is Canada’s national metabolomics laboratory, responsible for providing the best services in metabolomics analysis, including analytical/quantitative, international metabolomics analysis, and bioinformatics support to Canadian companies, researchers, and practitioners, leading to the growth of the metabolomics market.
• Metabolomics is emerging as an attractive tool for the discovery of biomarkers of diabetes and its complications, as metabolites can provide information about the underlying disease and development.

Driver

Advancing Biotechnology

Metabolomics is increasingly recognized as an important enabler in biotechnological advances, bridging the gap between genotype and phenotype to provide a deeper understanding of cellular function. Its applications cover a wide range of areas, including phenotyping genetically modified plants, testing genetic diversity, determining gene function, and monitoring responses to biotic and abiotic stresses. Metabolomics not only helps discover new biological insights by identifying significant changes in metabolites but also supports the development of new biotechnological solutions. Analysis and data mining of metabolomics datasets can generate new perspectives for biotechnology and discover new targets, thereby accelerating the growth of the metabolomics market. This industry expansion highlights the importance of metabolomics in fields such as agriculture, health research, and the biotechnology industry, making it an important tool for future scientific and technological advancement.

Restraint

Challenges in Biomarker Identification

The biggest limitation to the growth of the metabolomics market is the difficulty associated with identifying biomarkers needed to understand changes in the body. This step is also important in metabolomics studies, as metabolite identification (especially from LC-MS data) is more difficult as libraries are not re-developed compared to GC-MS analysis. Furthermore, inconsistencies in analytical platforms, column types, gradients, and collision energies used in tandem mass spectrometry in the laboratory further complicate data comparison and reproducibility. These economic barriers hinder the general application and activation of metabolomics, making it difficult for the industry to grow and fully realize its potential across the market.

Opportunity

Advancing Nutrition Intervention

In recent years, the use of metabolomics in nutrition research has increased, leading to advances in personalized nutrition and public health research. These studies investigate the link between diet and health or disease, and the diet is related to the use of whole foods, specific foods, or products such as micronutrients or phytochemicals. However, measuring the impact of these interventions can be challenging because metabolic changes are so subtle and often difficult to detect. Metabolomics plays an important role in overcoming these challenges, identifying target biomarkers of dietary intake, developing personalized nutrition strategies, and supporting large-scale research studies to better understand the relationship between nutrition and health. Therefore, developing metabolomics applications in these areas will not only improve understanding of the role of nutrition in health but also create a significant time for the growth of the metabolomics market, positioning it as a leader in the field of nutrition, a key enabler of health innovation.

Regional Insights

North America Dominates the Global Metabolomics Market

North America is expected to lead the market during the forecast period as the number of chronic diseases in the United States is steadily increasing by 7 to 8 million people every 5 years. Chronic diseases affect 50% of the population, and their care accounts for more than 85% of medical expenses. This has become an epidemic. Increase access to quality healthcare. Nearly 50% of US consumers now consider health the most important thing in their daily lives, an increase from 42%. Healthcare in the United States, unlike any other industry, is a complex stakeholder system comprised of patients, payers, and providers. The country’s more than 6,600 biotech companies are committed to innovation to solve complex medical problems and save more lives. Investments in the medical field are vital, driving the growth of the metabolomics market.

Asia-Pacific is the Fastest Growing Region in the Metabolomics Market

Asia Pacific is expected to grow significantly during the forecast period as healthcare providers in the region adopt more technologies, including AI and cloud technology, in their standards of care. Increasing healthcare spending in Asia Pacific is inevitable. The growth of the metabolomics market is driven by the increasing demand for medical devices in the Asia Pacific, which can be attributed to several factors, such as a rapidly aging population, the arrival of a growing middle class, health information, and key government initiatives, thus leading the growth of market.

Segmental Insights

By Product & Service

By type, metabolomics instrument segments constitute the metabolomics market as they allow researchers to analyze non-volatile compounds without the need for derivatization to increase volatility, reduce the formation of fragment ions, and simplify the spectral description of complex compounds. While the bioinformatics tools and services segment is the fastest growing in the forecast period due to its ability to process raw spectral data, analytical analysis to identify major metabolites has potential nature linkages with metabolite data for metabolite identification and bioinformatics analysis.

Metabolomics combined with sophisticated bioinformatics analysis and with the application of mathematical modeling can generate a metabolic snapshot of patients. This is done to classify patients into subpopulations and subgroups based on disease and risk. This helps narrow down a list of individuals who require medical intervention and treatment.

By Application

The biomarker discovery segment held the largest share of the market in 2023. The utilization of metabolic biomarkers to test pathophysiological health status for patients has increased in several years, this acts as a major growth factor for the segment to expand. Moreover, the integration of advanced technologies and advancements in metabolomics are seen to promote the segment’s growth.

By Indication

The cancer segment led the metabolomics market in 2023, with the rising demand for advanced testing methods or detection methods for cancer is observed to sustain the segment’s growth during the forecast period. Moreover, the rising number of cancer therapies and rising number of cancer patients are major factors to promote the growth of the segment. Additionally, the increase in funding for cancer and other associated diseases studies is observed to expand the segment’s growth in the upcoming period.

By End-user

By application, the academic and research institutes segment dominates the metabolomics market, as there is great potential for metabolomics to be used in public research to assess the effects of nutrients, drugs, and environmental impacts. The pharmaceutical and biotechnology companies segment is fastest growing, as mass spectrometry-based metabolomics plays an important role in clinical research, disease treatment, medicine, animal research and plants, agricultural research, and food. Research methods include sample preparation, sample analysis, data analysis, and metabolic process analysis.

Recent Developments

• In September 2024, Trinity Biotech plc, a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including biosensors, announced that it had acquired Metabolomics Diagnostics, an Irish deep-tech company specializing in collaborations in the development of novel biomarkers. Solutions to complex diseases.
• In May 2024, Metabolon, Inc., a global leader in providing metabolomics solutions enabling a variety of life sciences, diagnostics, drug development, and precision medicine, released significant improvements to its service with a new 4-week project turnaround time.
• In June 2022, Ginkgo Bioworks, a leading horizontal platform for cell programming, announced that it had acquired assets from Bitome, a leading point-of-care metabolite company, to accelerate bioproduct development. Bitome has developed technology that uses machine learning to continuously monitor cell culture media, provide rapid insights into cell function, and optimize bioprocess optimization.
• In August 2024, Metabolon, Inc., a global leader in providing metabolomics solutions enabling a variety of life sciences, diagnostics, drug development, and precision medicine applications, is entering into a partnership with the Scottish Early Rheumatoid Arthritis (SERA) Research Study on the Prevalence of Mild Rheumatoid Arthritis may serve as biomarkers of disease risk, progression, and response to therapy in rheumatoid arthritis.
• In June 2024, 23andMe Holdings Inc., a preventive care and treatment company, and Nightingale Health Plc, a leader in biomarker and risk testing, announced a collaboration to test the efficacy and value of Nightingale Health’s clinically validated and cost-effective blood metabolomics panel with a cohort of 23andMe members.

Top Companies in Metabolomics Market

• Thermo Fisher
• Agilent
• Metabolon
• Shimadzu Corporation
• Bruker
• Waters Corporation
• Biotree
• LECO Corporation
• Biocrates Life Sciences AG
• Human Metabolome Technologies
• Metware
• Applied Protein Technology
• Creative Proteomics
• Diagnostic Solutions Laboratory

Segments Covered in Metabolomics Market

By Product and Service

• Metabolomics Instruments
• Separation Tools
  • Gas Chromatography
  • High-performance Liquid Chromatography
  • Ultra-performance Liquid Chromatography
  • Capillary Electrophoresis
• Detection Tools
  • Nuclear Magnetic Resonance (NMR) Spectroscopy
  • Mass Spectroscopy
  • Surface-based Mass Analysis

By Application

• Biomarker Discovery
• Drug Discovery
• Toxicology Testing
• Nutrogenomics
• Functional Genomics
• Personalized Medicine
• Others

By Indication

• Cancer
• Cardiovascular Disorders
• Neurological Disorders
• Metabolic Disorders
• Others

By End-user

• Academic and Research Institutes
• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations

By Geography

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait